Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Refining IFX doses does not facilitate sustained remission after treatment discontinuation

19 Nov 2019

A programmed treatment strategy of refining infliximab (IFX) doses based on baseline serum tumour necrosis factor α (TNF-α) falls flat in sustaining remission rate in rheumatoid arthritis patients after 1 year of IFX discontinuation, according to the results of the multicentre randomized RRRR* trial.

RRRR included 337 IFX-naïve rheumatoid arthritis patients with inadequate response to methotrexate (MTX). Of these patients, 170 were assigned to the programmed treatment group that received 3 mg/kg of IFX until week 6. After 14 weeks, the dose was adjusted based on baseline serum TNF-α levels until week 54. The remaining 167 patients were assigned to the standard treatment group that received 3 mg/kg of IFX.

Sixty-seven patients (39.4 percent) in the programmed group and 54 (32.3 percent) in the standard group achieved remission at week 54 and discontinued IFX treatment. There was no significant between-group difference in the primary endpoint of sustained remission off IFX treatment at week 106: 23.5 percent vs 21.6 percent, respectively (difference, 2.2 percent, 95 percent confidence interval [CI], −6.6 percent to 11.0 percent; p=0.631).

Baseline SDAI <26.0 emerged as a significant predictor of successfully sustained discontinuation of IFX at week 106.

The findings indicate that a programmed treatment strategy does not guarantee a favourable outcome in terms of deep remission. Researchers called for additional investigation to pinpoint the patient profile most likely to benefit from discontinuation of biological disease-modifying antirheumatic drugs.

*Remission induction by raising the dose of remicade in RA

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.